Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluvoxamine effect on inflammatory cytokines in ICU patients with COVID-19
IRCT20131115015405N4Phase 3Completed
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of fluvoxamine in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Shahid Beheshti University of Medical Sciences. Primary endpoints: Change in interleukin-6, Change in C-reactive protein and 1 more. Started Jul 2020; status: completed.
02
Drugs
fluvoxamine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on IRCT20131115015405N4.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20131115015405N4.